Pay in 4 interest-free payments of $7.02 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
Today Ely Lilly (LLY) announced the positive results on a phase 2 diabetes drug of theirs ( LY3298176 ) via a publication in The Lancet, a presentation at the annual meeting of the European Association for the Study of Diabetes (EASD) and the press release below: Lilly's Investigational Dual GIP and GLP-1 Receptor Agonist Shows Significant Reduction in HbA1c and Body Weight in People With Type 2 Diabetes The press release created a few headlines: Bloomberg: Diabetes Drug's Results Push Lilly to Look at Obesity Too Reuters: Lilly's diabetes drug data impresses, hurts rival Novo's shares The share price of Eli Lilly went up by 4% in an otherwise sour market and that of Danish rival Novo Nordisk (NOVO-B.CO) plummeted some 7-8%
However, if youre using it off-label for weight loss, you may have to pay out-of-pocket
Unmarked vials are unsafe
China represents the single largest diabetes patient population globally an estimated 141 million adults with diabetes and the ongoing premium tier pharmaceutical market expansion is creating growing GLP-1 access for urban, commercially insured Chinese patients
As a master detoxifier and the body's main endogenous antioxidant, glutathione can bind to many unwanted compounds and help remove them from the body
Our IV therapy delivers fast, safe, and lasting results
US$ 23.09
US$ 25.32
US$ 22.83
US$ 28.73
